We are live on ! Find out more
ZVRA icon

Zevra Therapeutics

11.39 USD
+0.39
3.55%
At close Updated Oct 9, 4:00 PM EDT
Pre-market
After hours
11.25
-0.14
1.23%
1 day
3.55%
5 days
13.79%
1 month
-5.4%
3 months
-18.29%
6 months
17.3%
Year to date
36.57%
1 year
5.27%
5 years
25.72%
10 years
-83.82%
 

About: Zevra Therapeutics Inc is a commercial-stage company with a late-stage pipeline committed to bringing life-changing therapeutics to people living with rare diseases. The Company is focused on expanding patient access, progressing its pipeline toward key milestones, and delivering meaningful outcomes for patients with unmet needs. The commercialization of its product, marketed in the United States for Niemann-Pick disease type C (NPC), a rare, progressive neurodegenerative disease, provides a corporate foundation and demonstrates its ability to advance therapies from development to market.

Employees: 61

News

Positive
Neutral
Negative
Sentiment 3-Months
Positive 12%
Neutral 84%
Negative 4%
Positive
Seeking Alpha
6 days ago
Zevra Therapeutics: Miplyffa Validates The Bull Case, Europe Still The Swing Factor
Zevra Therapeutics is a buy-rated, single-asset rare disease play with Miplyffa driving strong U.S. growth and early profitability. 2Q26 net revenue reached $39.7M, up 53% YoY, with Miplyffa contributing $30.2M and high patient retention supporting a durable franchise thesis. Management's diagnosis expansion efforts suggest the NPC addressable market may be up to 900 patients, extending the growth runway beyond initial estimates.
Zevra Therapeutics: Miplyffa Validates The Bull Case, Europe Still The Swing Factor
Neutral
Seeking Alpha
27 days ago
Zevra Therapeutics, Inc. (ZVRA) Presents at Morgan Stanley 24th Annual Global Healthcare Conference Transcript
Zevra Therapeutics, Inc. (ZVRA) Presents at Morgan Stanley 24th Annual Global Healthcare Conference Transcript
Zevra Therapeutics, Inc. (ZVRA) Presents at Morgan Stanley 24th Annual Global Healthcare Conference Transcript
Neutral
GlobeNewsWire
1 month ago
Zevra Therapeutics to Present at Upcoming Investor Conferences
BOSTON, Sept. 02, 2026 (GLOBE NEWSWIRE) -- Zevra Therapeutics, Inc. (NasdaqGS: ZVRA) (Zevra, or the Company), a commercial-stage company focused on bringing life-changing therapeutics to people living with rare diseases, today announced that members of Zevra's executive leadership team will present at the following investor conferences in New York, NY.
Zevra Therapeutics to Present at Upcoming Investor Conferences
Neutral
GlobeNewsWire
1 month ago
Zevra Therapeutics to Present New Long-Term Real-World Data on MIPLYFFA® in Niemann-Pick Disease Type C (NPC) at the 2026 SSIEM Annual Symposium
BOSTON, Aug. 25, 2026 (GLOBE NEWSWIRE) -- Zevra Therapeutics, Inc. (NasdaqGS: ZVRA) (Zevra, or the Company), a commercial-stage company focused on bringing life-changing therapeutics to people living with rare diseases, today announced the presentation of two posters featuring long-term real-world data on MIPLYFFA® (arimoclomol) for the treatment of Niemann-Pick disease type C (NPC) at the Society for the Study of Inborn Errors of Metabolism (SSIEM) Annual Symposium. “These presentations further expand the growing body of evidence supporting the long-term safety and effectiveness of arimoclomol in NPC,” said Caroline Hastings, MD, Professor of Pediatrics, UCSF Benioff Children's Hospital Oakland.
Zevra Therapeutics to Present New Long-Term Real-World Data on MIPLYFFA® in Niemann-Pick Disease Type C (NPC) at the 2026 SSIEM Annual Symposium
Neutral
GlobeNewsWire
1 month ago
Zevra Therapeutics Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
BOSTON, Mass., Aug. 21, 2026 (GLOBE NEWSWIRE) -- Zevra Therapeutics, Inc. (NasdaqGS: ZVRA) (Zevra, or the Company), a commercial-stage company focused on bringing life-changing therapeutics to people living with rare diseases, today announced that the Company has granted options to purchase an aggregate of 92,200 shares of the Company's common stock (the “Inducement Awards”) to four new employees pursuant to the Company's 2023 Employment Inducement Award Plan. Each Inducement Award vests over four years, with 25% vesting on the first anniversary of the employee's start date, and the remainder vesting in three equal annual installments thereafter (subject to each such employee's continued employment on each vesting date).
Zevra Therapeutics Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
Neutral
PRNewsWire
1 month ago
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Zevra Therapeutics, Inc. - ZVRA
NEW YORK, Aug. 13, 2026 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Zevra Therapeutics, Inc. ("Zevra" or the "Company") (NASDAQ: ZVRA). Such investors are advised to contact Danielle Peyton at [email protected] or 646-581-9980, ext.
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Zevra Therapeutics, Inc. - ZVRA
Neutral
GlobeNewsWire
2 months ago
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Zevra Therapeutics, Inc. - ZVRA
NEW YORK, Aug. 11, 2026 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of Zevra Therapeutics, Inc. (“Zevra” or the “Company”) (NASDAQ: ZVRA). Such investors are advised to contact Danielle Peyton at [email protected] or 646-581-9980, ext. 7980.
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Zevra Therapeutics, Inc. - ZVRA
Neutral
PRNewsWire
2 months ago
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Zevra Therapeutics, Inc. - ZVRA
NEW YORK, Aug. 6, 2026 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Zevra Therapeutics, Inc. ("Zevra" or the "Company") (NASDAQ: ZVRA). Such investors are advised to contact Danielle Peyton at [email protected] or 646-581-9980, ext.
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Zevra Therapeutics, Inc. - ZVRA
Neutral
MarketBeat
2 months ago
Zevra Therapeutics Q2 Earnings Call Highlights
Zevra Therapeutics NASDAQ: ZVRA reported second-quarter 2026 net revenue of $39.7 million, up 53% from $25.9 million a year earlier, driven primarily by U.S. sales of its Niemann-Pick disease type C treatment MIPLYFFA.
Zevra Therapeutics Q2 Earnings Call Highlights
Neutral
Seeking Alpha
2 months ago
Zevra Therapeutics, Inc. (ZVRA) Q2 2026 Earnings Call Transcript
Zevra Therapeutics, Inc. (ZVRA) Q2 2026 Earnings Call Transcript
Zevra Therapeutics, Inc. (ZVRA) Q2 2026 Earnings Call Transcript
Price charts implemented using Lightweight Charts™